Literature DB >> 215305

Overview of thymosin activity.

G D Marshall, T L Low, G B Thurman, S K Hu, J L Rossio, G Trivers, A L Goldstein.   

Abstract

Our current research program centers around the biologic and chemical characterization of the family of polypeptides present in thymosin fraction 5. A system of nomenclature has been developed and the peptides are being systematically isolated and chemically characterized. Thymosin fraction 5 and its component parts influence a variety of lymphocyte properties including cyclic nucleotide levels, migration inhibitory factor production, T-dependent antibody production, and expression of certain surface markers. Thymosin is being used in clinical trials to investigate its effects on immunodeficiency diseases, malignant diseases, and autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 215305

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  2 in total

1.  Immunomodulation and therapeutic characterization of thymosin fraction five.

Authors:  J E Talmadge; K A Uithoven; B F Lenz; M Chirigos
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

2.  Treatment of patients with small-cell lung cancer at the Memorial Sloan-Kettering Cancer Center, 1974-1979.

Authors:  R E Wittes; R B Natale; J S Sierocki; B S Hilaris
Journal:  World J Surg       Date:  1981-09       Impact factor: 3.352

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.